Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ResQ133A-NMIBC: Phase 1/2 Clinical Trial of Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

NCT06800963 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT06800963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06800963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ResQ133A-NMIBC: Phase 1/2 Clinical Trial of Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 15, 2025
Completion date
February 29, 2028
Enrollment
40 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

nmibc